IntroductionMET amplification is a rare, potentially actionable, primary oncogenic driver in patients with NSCLC.MethodsThe influence of MET on the clinical activity ALK, ROS1, and inhibitor, crizotinib (250 mg twice daily), was examined NSCLC (NCT00585195) who were enrolled into high (?4 MET-to-CEP7 ratio), medium (>2.2 to <4 or low (?1.8 ?2.2 ratio) categories. Retrospective next-generation s...
